Description
MDK6620, also known as BTYNB IMP1 Inhibitor. is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA).
Uses
BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA (IC50=5 μM). BTYNB exhibits selectivity and effectiveness against IMP1-postive cancer cell lines. BTYNB can be used for cancer research[1].
References
[1] Lily Mahapatra,et al. A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation. Transl Oncol DOI:
10.1016/j.tranon.2017.07.008
![2-{[(5-bromo-2-thienyl)methylene]amino}benzamide Structure](https://www.chemicalbook.com/CAS/20180702/GIF/304456-62-0.gif)
